In vitro activity of Exebacase (CF-301) against clinical Staphylococcus aureus surveillance isolates from the United States, Europe, and Latin America, 2015–2017
Lysins are direct lytic agents which act through enzymatic cell-wall-hydrolysis and represent
a potential new class of antimicrobial agents in development to treat antibiotic-resistant
bacterial infections. Exebacase (CF-301) is a first-in-class lysin now in clinical development
for the treatment of Staphylococcus aureus (S. aureus) bacteremia and infective endocarditis
(IE) when used in addition to conventional antibiotics. Exebacase and comparator antibiotics
were tested by broth microdilution against a set of 535 clinical MSSA and MRSA isolates …
a potential new class of antimicrobial agents in development to treat antibiotic-resistant
bacterial infections. Exebacase (CF-301) is a first-in-class lysin now in clinical development
for the treatment of Staphylococcus aureus (S. aureus) bacteremia and infective endocarditis
(IE) when used in addition to conventional antibiotics. Exebacase and comparator antibiotics
were tested by broth microdilution against a set of 535 clinical MSSA and MRSA isolates …